FDA: Immune Tx Monotherapy in Bladder Ca May Worsen Survival
(MedPage Today) -- Pembrolizumab, atezolizumab trials stop enrolling patients with low PD-L1
Source: MedPage Today Product Alert - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology